Scribe Therapeutics brings specificity challenge into focus for CRISPR cardiometabolic drugs
CRISPR can lower cholesterol. The harder test is whether Scribe can make durability, precision, and scalability work in common disease.
Arrowhead’s plozasiran clears CHMP: what a positive opinion for FCS means for siRNA’s regulatory arc in Europe
Plozasiran clears CHMP but the real test is reimbursement. Europe’s HTA bodies will now decide whether clinical FCS diagnosis is enough.